Scholars Central

Conference abstractPublished 13 Jul 2018

Untitled abstract

Authors: Roopam Jain

Sahurastra University, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: The development of alloantibodies complicates transfusion therapy in all multiply transfused patients including thalassemia, hemato-onco patients etc. Alloimmunisation to red cell antigens is one of the most important immunological transfusion reaction and causes delayed type of transfusion reaction. Increasing red cell transfusion requirement, iron deposit and development of alloantibodies complicates transfusion therapy in Hhemato-onco patients. Aims: (1) To investigate the frequency and distribution pattern of various types of irregular red cell alloantibodies in Hemato-oncology patients and (2) To determine the rate of development of red cell alloantibodies in Hemato-onco patients. Methods: A prospective study was conducted from January 2008 to December 2015 at three diffirent centre of india. Purposive sampling was done and all patients diagnosed to have thalassemia major were included in the study. 78 diagnosed thalassemia major patients were included in this study and samples collected and investigated for the development of alloantibody to red cell antigens by using matrix gel system. Five to seven ml of blood was collected in plain tube and serum was separated. Separated serum was taken in two aliquots, labeled properly and stored in two different boxes at -30 ℃ in deep freezer, till the antibody screening and identification performed. Tests for antibody screening and identification were performed on preserved sample to investigate prevalence of red cell alloimmunization by standardized laboratory techniques by same person. Antibody screening was carried out on serum employing commercial three-cell panel using standardized blood bank techniques. If patients were found to have an irregular red cell alloantibody then the antibody identification was performed using commercial 11 cell panel cells. Results: A total of 100 patients were included in the study. 53 patients were males and 47 females. Mean age was 10.83 years. Irregular red cell alloantibodies were found in 9 (9%). Mean age of patients who developed red cell alloantibody was 7.9 years. Three (33.3%) patients developed anti-D while two (22.2%) had non-specific antibody. One patient each developed anti-K (11.1%) and anti-E (11.1%). Two had anti-D (11.1%) and anti-C while the other one (11.1%) developed anti-E and anti-K. Conclusion: Red cell alloimmunisation should be kept in mind in the patients receiving multiple transfusions. We concluded that there is relatively high rate of alloimmunization in our set of patients when compared to data from our region. In present study, alloimmunisation rate was 9%. Mean transfusion duration in these patients was 22.18 days, probably due to presence of alloantibody. We also suggest that red cell alloimmunization should not be overlooked in patients receiving regular blood transfusion. RBC alloantibody detection on regular interval and antibody negative blood transfusion is strongly recommended in transfusion dependent hemato-onco patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Roopam Jain”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels